GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Top Stock Reports for Wells Fargo, Honeywell & Northrop Grumman
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo & Company (WFC), Honeywell International Inc. (HON) and Northrop Grumman Corporation (NOC).
Sanofi (SNY), GSK Receive EU Approval for COVID-19 Vaccine
by Zacks Equity Research
Sanofi (SNY) and partner GSK's COVID-19 vaccine receives authorization in the European Union for use as a booster in adults aged 18 years and older.
Pharma Stock Roundup: Q3 Earnings of BAYRY, AZN, EU Nod for AZN, SNY RSV Vaccine
by Kinjel Shah
Bayer (BAYRY) and AstraZeneca (AZN) announce third-quarter results. AstraZeneca and Sanofi's (SNY) RSV vaccine, nirsevimab gets approval in Europe.
Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.
Theravance (TBPH) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Theravance (TBPH) reports a narrower-than-expected loss for the third quarter of 2022. Revenues decline year over year.
GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
by Zacks Equity Research
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 21.11% and 18.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GSK Gears Up to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Sales of GSK's vaccine segment, especially meningitis and influenza vaccines, are likely to have been an important contributor to third-quarter 2022 sales.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $33.27 in the latest trading session, marking a +1.68% move from the prior day.
Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod
by Kinjel Shah
Novartis (NVS) and Merck (MRK) announce Q3 results. FDA approves J&J's (JNJ) multiple myeloma candidate, Tecvayli.
Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $32.24 in the latest trading session, marking a +1.51% move from the prior day.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $31.31, moving +0.19% from the previous trading session.
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults
by Zacks Equity Research
GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna, Merck and GSK
by Zacks Equity Research
Pfizer, BioNTech, Moderna, Merck and GSK are included in this Analyst Blog.
GSK (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
GSK (GSK) closed at $30.65 in the latest trading session, marking a +0.92% move from the prior day.
Pharma Stock Roundup: FDA Oks Omicron Jabs for Kids, MRK, MRNA Partner for Cancer Jab
by Kinjel Shah
FDA grants emergency approval to Pfizer (PFE) and Moderna's (MRNA) Omicron BA.4, BA.5 adapted COVID-19 booster for use in kids. Merck (MRK) and Moderna to jointly develop an mRNA-based cancer vaccine.
Gilead (GILD) Trodelvy Label Expansion sBLA Gets Priority Review
by Zacks Equity Research
Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.
Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?
by Zacks Equity Research
Gilead (GILD) is having a good run despite the volatility on a string of positive updates.
GSK's (GSK) Boostrix Gets FDA Nod for Pertussis in Newborns
by Zacks Equity Research
Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.
GSK (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GSK (GSK) closed the most recent trading day at $30.11, moving +0.37% from the previous trading session.
Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract
by Zacks Equity Research
VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
by Zacks Equity Research
GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.